(R)-2-[4-(3-chlorobenzyloxy)benzylamino]propanamide methanesulfonate | 878379-15-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-[4-(3-chlorobenzyloxy)benzylamino]propanamide methanesulfonate
• 英文别名: (2R)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid
• CAS: 878379-15-8
• 化学式: CH₄O₃S*C₁₇H₁₉ClN₂O₂
• 分子量: 414.91
• InChiKey: ZASWIMBXLVJJOD-UTONKHPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.39
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
  申请人：Barbanti Elena

  公开号：US20080096965A1

  公开（公告）日：2008-04-24

  The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active assodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.

  本发明涉及选定的（R）-2-[(卤代苯氧基)苯基氨基]-丙酰胺及其药学上可接受的盐的使用，用于制备药物，这些药物是选择性作用于钠和/或钙通道调节剂，因此有助于预防、缓解和治疗各种病理状况，包括疼痛、偏头痛、周围疾病、心血管疾病、影响全身系统的炎症过程、影响皮肤和相关组织的疾病、呼吸系统疾病、免疫和内分泌系统疾病、胃肠道、泌尿生殖系统、代谢和癫痫疾病，上述机制已被描述为发挥病理作用。
• USE OF (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES FOR THE MANUFACTURE OF MEDICAMENTS ACTIVE AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS
  申请人：Barbanti Elena

  公开号：US20110184068A1

  公开（公告）日：2011-07-28

  The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.

  本发明涉及选择性使用(R)-2-[(卤代苄氧)苯基甲酰胺]及其药学上可接受的盐制备药物，该药物具有选择性作为钠和/或钙通道调节剂的活性，因此可用于预防、缓解和治疗广泛的病理情况，包括疼痛、偏头痛、周围疾病、心血管疾病、影响所有身体系统的炎症过程、影响皮肤及相关组织的疾病、呼吸系统疾病、免疫和内分泌系统疾病、胃肠道、泌尿生殖、代谢和癫痫障碍，其中上述机制已被描述为发挥病理作用。
• USE OF (R)-(HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP1809271B1

  公开（公告）日：2010-06-16
• (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDES AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP1809271A2

  公开（公告）日：2007-07-25
• [EN] USE OF (HALOBENZYLOXY)BENZYLAMINO-PROPANAMIDES FOR THE MANUFACTURE OF MEDICAMENTS ACTIVE AS SODIUM AND/OR CALCIUM CHANNEL SELECTIVE MODULATORS<br/>[FR] UTILISATION DE (HALOBENZYLOXY)BENZYLAMINO-PROPANAMIDES POUR LA FABRICATION DE MEDICAMENTS ACTIFS COMME MODULATEURS SELECTIFS DES CANAUX SODIQUES ET/OU CALCIQUES
  申请人：NEWRON PHARM SPA

  公开号：WO2006027052A2

  公开（公告）日：2006-03-16

  The invention relates to the use of selected (R) -2­-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active assodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.